Vertex had already announced results of the first corrector and moved into a large, phase III clinical trial with the hope of moving the proteins into a place where Kalydeco could make them work better.
Instead, Genta skipped directly to large-scale "phase-III" trials comparing Genasense to standard chemotherapy on many hundreds of patients in an all-or-nothing bet to prove the drug worked.
Big companies are in decline because they have gone through their innovative phase and are now failing by and large to see themselves as conduits of innovation.
Ahead of last week's ICANN meeting in Yokohama, Japan, however, controversy erupted when the group's staff proposed amending ICANN's bylaws not just to conduct the study but also to phase out the existence of the nine at-large directors within two years.